CMTA Headlines:

CMT1A_Breakthrough_274x383

CMT1A Research Breakthrough!

Scientists at Ionis Pharmaceuticals, in collaboration with the Charcot-Marie-Tooth Association, have identified a promising early-stage therapeutic approach with antisense technology for CMT Type 1A (CMT1A), the most common form of the disease, accounting for half of all cases. Read more …

Breakthroughs to a Cure

Breakthroughs to a Cure

Thanks to your support of the CMTA’s research initiative, promising therapeutic approaches for CMT1A have been identified. Studies in two laboratory models of CMT1A not only stopped progression of the disease, but also showed improvement of some symptoms. And, while the 1A project is furthest along the path to drug delivery, projects addressing 90% of all cases of CMT, including types 1B, 1X, 2A, 2E and 4, are also delivering promising results using cutting-edge techniques. To deliver the first treatments for CMT, we need funding for clinical trials and further drug development. Learn more…

Russ Mitchell

Fighting for Claire and Her Generation

Russ Mitchell talks for a living. He’s a sportscaster. But until recently he didn’t talk about his CMT with anyone outside his family. That changed in a big way on September 1, when he added his voice to the chorus of voices spreading the word about CMT for Awareness Month. Read his story…

Breakthroughs to a Cure

Breakthroughs to a Cure

Studies in two laboratory models of CMT1A not only stopped progression of the disease, but also showed improvement of some symptoms. To deliver the first treatments for CMT1A and other types of CMT, we need funding for clinical trials and further drug development.

What is CMT?

Charcot-Marie-Tooth, or CMT, is the most commonly inherited peripheral neuropathy and affects an estimated 2.8 million people.

Find Your Local Branch

The CMTA has over 80 Branches across North America to support people with CMT, raise awareness, and fund research. Connect with your nearest Branch today!

Fundraise to End CMT

Without fundraising and community volunteers, the CMTA would not be the leading force in CMT Research that it is today. Are you ready to make an impact?

Shop Our Store

Visit our store to see some of the most fun and fashionable ways to raise awareness!

The CMTA’s STAR (Strategy to Accelerate Research)

STAR Research
The CMTA’s vision is a world where patients with CMT neuropathies have therapies available to them to manage or modify their disease. That vision is poised to become reality as STAR pushes the research forward at an ever-increasing speed.

STAR – Disease Project Team Updates

Type1A
The CMTA’s research is done in teams consisting of academic labs and clinical centers sponsored by the CMTA (STAR members), working together and with alliance partners in consortium team efforts. STAR Teams are sponsored by the CMTA via a rapid process of expert review, following invitation of proposals for targeted translational efforts. All sponsorship aims to directly aid the advancement of CMT therapies.
ourpartners_94x32
Balance Walking
genedx_94x32
Kinetic Research
aetrex_94x32
cosysoles_94x32
hangerclinic_94x32
ler_94x32
allard_94x32
footsolutions_94x32
invitae_94x32
sweetrishsgranola_94x32_94x32
turbomed_94x32
nord-member-org.199x66
Charity Navigator
Guide Star Gold Seal
ICA_bestinamerica_90x150